mutations e484 k n terminal domain changes carried variants affect antibodies generated vaccines previous infection recognize says mclellan biotech firm moderna cambridge massachusetts developed rna based vaccine said expect jabs work uk variant tests way pressing question changes alter real world effectiveness vaccines says jesse bloom viral evolutionary biologist fred hutchinson cancer research center seattle washington 4 january preprint team reported e484 k mutations escape recognition antibodies peoples convalescent sera varying degrees bloom scientists hopeful mutations variants will not substantially weaken performance vaccines shots tend elicit whopping levels neutralizing antibodies small drop potency variants not matter arms immune response triggered